TD Cowen has recently initiated TG Therapeutics Inc common stock (TGTX) stock to Buy rating, as announced on October 29, 2024, according to Finviz. Earlier, on August 2, 2023, Goldman had raised the stock from a Sell to Neutral, setting a price target of $12 for TGTX stock. Jefferies also resumed Buy rating with a price target of $40. Additionally, BofA Securities initiated Underperform rating on May 20, 2022, with a target price of $5. B. Riley Securities analysts, in their report published on February 23, 2022, also reiterated Buy rating and set a price target of $35 for TG Therapeutics Inc common stock’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
TG Therapeutics Inc common stock (TGTX) Stock Trading Recap
On Tuesday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $25.86 which represents a slight increase of $1.50 or 6.16% from the prior close of $24.36. The stock opened at $24.49 and touched a low of $23.6 during the day, reaching a high of $26.02. The volume of shares traded was 3.95 million exceeding the average volume of 3.71 million.
TGTX Stock Performance and Moving Averages
In recent trading, TG Therapeutics Inc common stock (TGTX) stock price has shown some volatility, fluctuating 0.58% over the last five trades and 21.35% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 50.52%, and it has gained 29.36% in the previous three months. Currently, TGTX is trading at 7.58%, 9.76%, and 38.04% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, TGTX, a Healthcare sector stock, is trading -4.19% below its 52-week high but remains 163.61% above its 52-week low. The Average True Range (ATR) (14 days) of 1.48 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
TG Therapeutics Inc common stock’s Profitability and Valuation Ratios
TG Therapeutics Inc common stock’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -0.19% and a profit margin of -5.42%, with a gross margin of 50.52%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, TG Therapeutics Inc common stock’s market capitalization stands at $4.00 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 26.66. Additionally, the Price-to-Sales Ratio is 15.12, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 22.55, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.88% of TG Therapeutics Inc common stock (TGTX)’s shares, while financial institutions hold 59.97%.
Notable insider trades include Lonial Sagar, Director at TG Therapeutics Inc common stock (TGTX), who sold 16348 shares on Jun 20 ’24, at $16.87 each, totaling $0.28 million. On Jun 17 ’24, Lonial Sagar, Director, sold 9585 shares for $16.39 each, amounting to $0.16 million. Additionally, on Mar 12 ’24, Charney Laurence N sold 22000 shares at $15.97 each, generating $0.35 million.
